Abstract A42
Introduction
Although epidermal growth factor receptor (EGFR) T790M mutation accounts for majority of the resistance to the first generation EGFR tyrosine kinase inhibitors (TKIs), activation of the MET pathway through increased expression of hepatocyte growth factor (HGF) or amplification of MET (the HGF receptor) has also been identified as a resistance Abstract A42 hepatocyte growth factor (HGF) or amplification of MET (the HGF receptor) has also been identified as a resistance mechanism in patients (Sadig and Salgia, 2013; Straussman et al., 2012; Wilson et al., 2012; Corso et al., 2013) . Effective treatment of patients that have progressed on first-generation TKIs requires diagnostic assays that detect the major resistance mechanisms and direct therapy selection. We have developed immunohistochemistry (IHC) assays to detect both HGF and MET protein expression in formalin-fixed paraffin-embedded (FFPE) tissues, and evaluated expression levels in patients previously treated with EGFR TKIs or chemotherapy.
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Materials and Methods
IHC assays were developed using the Ventana Benchmark. The MET (SP44) antibody was obtained from Ventana Medical Systems. The assay was validated using the recommended protocol supplied by the vendor. Five different HGF antibodies purchased from three vendors (IBL, LifeSpan Bio, and Santa Cruz Biotechnology) were evaluated using cell line pellets genetically engineered to over-express HGF as well as the parental cell line (Figure 1 MET IHC: Both membranous and cytoplasmic staining was defined as positive. The expression is scored on the basis of intensity and fraction of positive cells. The intensity score is defined as follows: 0 -no appreciable staining in the tumor cells; 1 -faint/barely visible partial membrane and cytoplasmic staining; 2 -weak to moderate staining; 3 -strong staining. Samples that scored ≥2+ in the ≥50% of tumor were considered c-Met positive. MMD-2-2-148 75% IV a TX1 Platinum-B dD bl t 0 N e gative weak positive 1+ 10 5 µg/mL 2 µg/mL 1 µg/mL HGF IHC: Cytoplasmic staining was defined as positive. The expression was scored predominantly based on intensity as defined for MET above. In addition, H-score was determined for the set of lung cancer specimens. Figure 2 . The three antibodies that displayed specificity for HGF over-expressing cell pellets were further evaluated for sensitivity and specificity using gall bladder FFPE tissue. Panels A-C display the staining patterns observed with the three antibodies. The IBL H487 antibody gave the best IHC signal compared to the other two antibodies based on intensity and specificity of the staining pattern. We tested several dilutions of the H487 antibody to determine the optimal concentration for further analysis (Panels C-E). 
Conclusions
We have developed robust assays for evaluation of MET and HGF protein expression in FFPE sections and applied these assays in analyzing 25 NSCLC patient specimens A more expansive dataset potentially evaluating factors 
